尼莫地平序贯疗法联合瑞舒伐他汀治疗高血压性脑出血

Abstract: Objective To observe and explore the clinical effect of combined nimodipine sequential therapy and rosuvastatin treatment in patients with hypertensive intracerebral hemorrhage. Methods Medical records of Jia County Hospital of Traditional Chinese Medicine were collected from May 2022 to May 2025. A total of 80 patients with hypertensive cerebral hemorrhage were included. They were grouped based on the random number table method, namely the conventional group (a total of 40 cases, treated with sequential nimodipine therapy) and the observation group (a total of 40 cases, treated with sequential nimodipine therapy combined with rosuvastatin). The total therapeutic efficiency was evaluated after continuous medication for 14 days. The National Institutes of Health Stroke Scale (NIHSS) was compared. The hematoma volume and intracranial pressure were measured. The inflammation-stress indicators [tumor necrosis factor -α (TNF-α), amyloid A (SAA), malondialdehyde (MDA) ] were detected to observe whether there were any adverse reactions. Results The therapeutic efficiency of the observation group after continuous medication for 14 days was 92.50%, which was higher than that of the conventional group (P＜0.05). Before treatment, there were no significant differences in the total score of NIHSS, hematoma volume, intracranial pressure, and the detection levels of inflammation-stress indicators between the two groups. After 14 days of treatment, the total score of NIHSS, hematoma volume, intracranial pressure, and the detection levels of TNF-α, SAA, and MDA in both groups further decreased. However, the levels in the observation group were significantly lower than those in the conventional group (P＜0.05). There was no significant difference in the adverse reactions that occurred during the medication treatment between the observation group and the conventional group (P＞0.05). Conclusion The combined application of nimodipine sequential therapy and rosuvastatin in patients with hypertensive intracerebral hemorrhage has an ideal clinical effect. It can promote the improvement of neurological function, reduce the volume of hematoma, lower intracranial pressure, alleviate inflammatory and stress injury, and no serious adverse reactions have occurred. This reflects that the combined medication regimen has high safety and can be referred to.